头孢噻肟钠舒巴坦钠腹腔注射治疗肝硬化合并腹水感染的临床效果  

Clinical effect of intraperitoneal injection of cefotaxime sodium and sulbactam sodium in the treatment of liver cirrhosis complicated with ascites infection

作　　者：冼彩连[1] 陈墅圳[1] XIAN Cailian;CHEN Shuzhen(Department of Gastroenterology,Guangzhou First People’s Hospital,Guangdong Province,Guangzhou 510110,China)

机构地区：[1]广州市第一人民医院消化内科,510110

出　　处：《临床合理用药杂志》2022年第25期32-35,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的 观察头孢噻肟钠舒巴坦钠腹腔注射治疗肝硬化合并腹水感染的临床效果。方法 选取2019年3月—2021年3月在广州市第一人民医院就诊的肝硬化合并腹水感染患者145例,采用随机数字表法分为研究组73例和对照组72例。对照组给予常规治疗,研究组在常规治疗的基础上给予头孢噻肟钠舒巴坦钠腹腔注射治疗,2组均连续治疗5周。比较2组患者的临床疗效,治疗前与治疗2周、5周后肝功能、炎性因子水平、免疫功能及并发症。结果 研究组患者的总有效率为94.52%,高于对照组的79.17%(χ^(2)=7.505,P=0.006)。治疗2周、5周后,2组患者白蛋白(Alb)水平均高于治疗前,丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、总胆红素(TBil)水平均低于治疗前,且研究组升高/降低幅度均大于对照组,差异均有统计学意义(P<0.01);2组患者白介素-1(IL-1)、白介素-6(IL-6)及白介素-8(IL-8)水平均低于治疗前,且研究组均低于对照组,差异均有统计学意义(P<0.01);2组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高于治疗前,CD8^(+)水平均低于治疗前,且研究组升高/降低幅度均大于对照组,差异均有统计学意义(P<0.01)。对照组与研究组并发症总发生率比较差异无统计学意义(5.56%vs.2.74%,χ^(2)=0.725,P=0.395)。结论 头孢噻肟钠舒巴坦钠腹腔注射治疗肝硬化合并腹水感染的效果较好,可有效改善患者的肝功能,抑制患者机体炎性反应,增强患者的免疫功能,可避免消化道出血、肝性脑病并发症的发生。Objective To observe the clinical effect of intraperitoneal injection of cefotaxime sodium and sulbactam sodium in the treatment of liver cirrhosis complicated with ascites infection.Methods A total of 145 patients with liver cirrhosis complicated by ascites infection who were treated in Guangzhou First People′s Hospital from March 2019 to March2021 were selected.According to the random number table method,they were divided into the study group of 73 cases and the control group of 72 cases.The control group was given conventional treatment,and the study group was given intraperitoneal injection of cefotaxime sodium and sulbactam sodium on the basis of conventional treatment,both groups were given continuous treatment for 5 weeks.The clinical efficacy,liver function,inflammatory factor levels,immune function and complications before treatment,2 weeks and 5 weeks after treatment were compared between the two groups.Results The total effective rate in the study group was 94.52%,which was higher than 79.17%in the control group(χ^(2)=7.505,P=0.006).After 2 weeks and 5 weeks of treatment,the levels of albumin(Alb)in the two groups were higher than those before treatment,the levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST)and total bilirubin(TBil)were lower than those before treatment,the increase/decrease in the study group was greater than that in the control group,and the differences were statistically significant(P<0.01);The levels of interleukin-1(IL-1),interleukin-6(IL-6)and interleukin-8(IL-8)in the two groups were lower than before treatment,and the study group was lower than the control group,the differences were statistically significant(P<0.01);The levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the two groups were all higher than those before treatment,and the levels of CD8^(+)were lower than those before treatment,and the increase/decrease in the study group was greater than that in the control group,the differences were all statistically significant(P<0.01).There was no significant di

关 键 词：肝硬化 腹水感染 头孢噻肟钠舒巴坦钠 腹腔注射 肝功能 

分 类 号：R575.2[医药卫生—消化系统]